• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

量化 SARS-CoV-2 病毒载量与传染性之间的关系。

Quantifying the relationship between SARS-CoV-2 viral load and infectiousness.

机构信息

Université de Paris, IAME, INSERM, Paris, France.

Centre for Interdisciplinary Research in Biology (CIRB), Collège de France, CNRS, INSERM, PSL Research University, Paris, France.

出版信息

Elife. 2021 Sep 27;10:e69302. doi: 10.7554/eLife.69302.

DOI:10.7554/eLife.69302
PMID:34569939
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8476126/
Abstract

The relationship between SARS-CoV-2 viral load and infectiousness is poorly known. Using data from a cohort of cases and high-risk contacts, we reconstructed viral load at the time of contact and inferred the probability of infection. The effect of viral load was larger in household contacts than in non-household contacts, with a transmission probability as large as 48% when the viral load was greater than 10 copies per mL. The transmission probability peaked at symptom onset, with a mean probability of transmission of 29%, with large individual variations. The model also projects the effects of variants on disease transmission. Based on the current knowledge that viral load is increased by two- to eightfold with variants of concern and assuming no changes in the pattern of contacts across variants, the model predicts that larger viral load levels could lead to a relative increase in the probability of transmission of 24% to 58% in household contacts, and of 15% to 39% in non-household contacts.

摘要

SARS-CoV-2 病毒载量与传染性之间的关系尚不清楚。本研究利用病例和高危接触者队列数据,重建了接触时的病毒载量,并推断了感染的概率。病毒载量对家庭接触者的影响大于非家庭接触者,当病毒载量大于 10 拷贝/毫升时,传播概率高达 48%。传播概率在症状出现时达到峰值,平均传播概率为 29%,个体差异较大。该模型还预测了变异对疾病传播的影响。基于目前的知识,即病毒载量会因关注的变异而增加 2 至 8 倍,并且假设不同变异的接触模式没有变化,该模型预测,更大的病毒载量水平可能导致家庭接触者的传播概率相对增加 24%至 58%,非家庭接触者的传播概率相对增加 15%至 39%。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc24/8476126/f27e070fa77f/elife-69302-fig4-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc24/8476126/a4793bdb325a/elife-69302-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc24/8476126/aa8ab242b407/elife-69302-fig1-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc24/8476126/865899945cfd/elife-69302-fig1-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc24/8476126/7bc7e08d478f/elife-69302-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc24/8476126/057ffd7f6ea1/elife-69302-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc24/8476126/4cfb7c278aba/elife-69302-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc24/8476126/414bfd73a480/elife-69302-fig4-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc24/8476126/f27e070fa77f/elife-69302-fig4-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc24/8476126/a4793bdb325a/elife-69302-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc24/8476126/aa8ab242b407/elife-69302-fig1-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc24/8476126/865899945cfd/elife-69302-fig1-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc24/8476126/7bc7e08d478f/elife-69302-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc24/8476126/057ffd7f6ea1/elife-69302-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc24/8476126/4cfb7c278aba/elife-69302-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc24/8476126/414bfd73a480/elife-69302-fig4-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc24/8476126/f27e070fa77f/elife-69302-fig4-figsupp2.jpg

相似文献

1
Quantifying the relationship between SARS-CoV-2 viral load and infectiousness.量化 SARS-CoV-2 病毒载量与传染性之间的关系。
Elife. 2021 Sep 27;10:e69302. doi: 10.7554/eLife.69302.
2
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.英国未接种和接种疫苗人群中 SARS-CoV-2 德尔塔(B.1.617.2)变异株的社区传播和病毒载量动力学:一项前瞻性、纵向、队列研究。
Lancet Infect Dis. 2022 Feb;22(2):183-195. doi: 10.1016/S1473-3099(21)00648-4. Epub 2021 Oct 29.
3
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study.西班牙加泰罗尼亚 282 起聚集性 COVID-19 传播:一项队列研究。
Lancet Infect Dis. 2021 May;21(5):629-636. doi: 10.1016/S1473-3099(20)30985-3. Epub 2021 Feb 2.
4
SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study.SARS-CoV-2 血清流行率和高危密切接触者的传播风险因素:一项回顾性队列研究。
Lancet Infect Dis. 2021 Mar;21(3):333-343. doi: 10.1016/S1473-3099(20)30833-1. Epub 2020 Nov 2.
5
Infection and disease spectrum in individuals with household exposure to SARS-CoV-2: A family cluster cohort study.家庭接触 SARS-CoV-2 个体的感染和疾病谱:家庭簇队列研究。
J Med Virol. 2021 May;93(5):3033-3046. doi: 10.1002/jmv.26847. Epub 2021 Feb 12.
6
Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study.SARS-CoV-2 传染性的发病和窗口期,以及与症状发作的时间相关性:一项前瞻性、纵向、社区队列研究。
Lancet Respir Med. 2022 Nov;10(11):1061-1073. doi: 10.1016/S2213-2600(22)00226-0. Epub 2022 Aug 18.
7
Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study.家庭二次感染 COVID-19 的发生率及其在中国广州的相关决定因素:一项回顾性队列研究。
Lancet Infect Dis. 2020 Oct;20(10):1141-1150. doi: 10.1016/S1473-3099(20)30471-0. Epub 2020 Jun 17.
8
Personal characteristics and transmission dynamics associated with SARS-CoV-2 semi-quantitative PCR test results: an observational study from Belgium, 2021-2022.个人特征与 SARS-CoV-2 半定量 PCR 检测结果相关因素:2021-2022 年比利时的一项观察性研究。
Front Public Health. 2024 Sep 10;12:1429021. doi: 10.3389/fpubh.2024.1429021. eCollection 2024.
9
Inferring transmission risk of respiratory viral infection from the viral load kinetics of SARS-CoV-2, England, 2020 to 2021 and influenza A virus, Hong Kong, 2008 to 2012.根据2020年至2021年英国新冠病毒(SARS-CoV-2)以及2008年至2012年中国香港甲型流感病毒的病毒载量动力学推断呼吸道病毒感染的传播风险
Euro Surveill. 2025 Feb;30(6). doi: 10.2807/1560-7917.ES.2025.30.6.2400234.
10
Estimating infectiousness throughout SARS-CoV-2 infection course.估算 SARS-CoV-2 感染全程的传染性。
Science. 2021 Jul 9;373(6551). doi: 10.1126/science.abi5273. Epub 2021 May 25.

引用本文的文献

1
A fundamental limit to the effectiveness of traveller screening with molecular tests.分子检测用于旅行者筛查有效性的一个基本限制。
Epidemiol Infect. 2025 Aug 15;153:e95. doi: 10.1017/S0950268825100381.
2
Should public health policy exempt cases with low viral load from isolation during an epidemic?: a modelling study.公共卫生政策是否应在疫情期间豁免病毒载量低的病例进行隔离?一项建模研究。
Infect Dis Model. 2025 Jul 9;10(4):1307-1321. doi: 10.1016/j.idm.2025.07.003. eCollection 2025 Dec.
3
Nasal inhalation of antiviral microparticulate powders to target early infection of upper airways.

本文引用的文献

1
Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness.每日纵向采样 SARS-CoV-2 感染揭示了传染性的显著异质性。
Nat Microbiol. 2022 May;7(5):640-652. doi: 10.1038/s41564-022-01105-z. Epub 2022 Apr 28.
2
Variant-specific SARS-CoV-2 within-host kinetics.宿主内变异 SARS-CoV-2 的动力学特征。
J Med Virol. 2022 Aug;94(8):3625-3633. doi: 10.1002/jmv.27757. Epub 2022 May 5.
3
The N501Y spike substitution enhances SARS-CoV-2 infection and transmission.N501Y 刺突突变增强了 SARS-CoV-2 的感染和传播。
经鼻腔吸入抗病毒微粒粉末以靶向治疗上呼吸道早期感染。
Drug Deliv Transl Res. 2025 Jul 15. doi: 10.1007/s13346-025-01916-7.
4
Viral Dynamic Models During COVID-19: Are We Ready for the Next Pandemic?新冠疫情期间的病毒动力学模型:我们是否为下一次大流行做好准备?
CPT Pharmacometrics Syst Pharmacol. 2025 Aug;14(8):1289-1297. doi: 10.1002/psp4.70055. Epub 2025 Jun 2.
5
Post-recovery viral shedding shapes wastewater-based epidemiological inferences.恢复后的病毒脱落影响基于废水的流行病学推断。
Commun Med (Lond). 2025 May 22;5(1):193. doi: 10.1038/s43856-025-00908-5.
6
Interplay Between Viral Shedding, Age, and Symptoms in Individual Infectivity of COVID-19 Breakthrough Infections in Households.家庭中新冠病毒突破性感染个体传染性中病毒 shedding、年龄和症状之间的相互作用
Vaccines (Basel). 2025 Mar 19;13(3):329. doi: 10.3390/vaccines13030329.
7
SARS-CoV-2 epidemiology, kinetics, and evolution: A narrative review.严重急性呼吸综合征冠状病毒2型的流行病学、动力学及进化:一篇综述
Virulence. 2025 Dec;16(1):2480633. doi: 10.1080/21505594.2025.2480633. Epub 2025 Apr 8.
8
Enhanced testing can substantially improve defense against several types of respiratory virus pandemic.加强检测可大幅提升对多种呼吸道病毒大流行的防御能力。
Epidemics. 2025 Mar;50:100812. doi: 10.1016/j.epidem.2024.100812. Epub 2025 Jan 13.
9
Azelastine Nasal Spray in Non-Hospitalized Subjects with Mild COVID-19 Infection: A Randomized Placebo-Controlled, Parallel-Group, Multicentric, Phase II Clinical Trial.阿扎司汀鼻喷雾剂用于非住院轻度新型冠状病毒肺炎感染患者:一项随机、安慰剂对照、平行组、多中心II期临床试验。
Viruses. 2024 Dec 13;16(12):1914. doi: 10.3390/v16121914.
10
A modeling study to define guidelines for antigen screening in schools and workplaces to mitigate COVID-19 outbreaks.一项建模研究,旨在确定学校和工作场所抗原筛查的指导方针,以减轻新冠疫情的爆发。
Commun Med (Lond). 2025 Jan 3;5(1):2. doi: 10.1038/s43856-024-00716-3.
Nature. 2022 Feb;602(7896):294-299. doi: 10.1038/s41586-021-04245-0. Epub 2021 Nov 24.
4
SARS-CoV-2 variants of concern are associated with lower RT-PCR amplification cycles between January and March 2021 in France.2021年1月至3月期间,法国的新冠病毒变异株与较低的逆转录聚合酶链反应(RT-PCR)扩增循环数相关。
Int J Infect Dis. 2021 Dec;113:12-14. doi: 10.1016/j.ijid.2021.09.076. Epub 2021 Oct 1.
5
SARS-CoV-2 viral dynamics in infections with Alpha and Beta variants of concern in the French community.法国社区中关注的阿尔法和贝塔变异株感染中的新冠病毒动力学。
J Infect. 2022 Jan;84(1):94-118. doi: 10.1016/j.jinf.2021.07.031. Epub 2021 Jul 28.
6
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.BNT162b2 和 mRNA-1273 疫苗对新冠病毒的预防和衰减作用。
N Engl J Med. 2021 Jul 22;385(4):320-329. doi: 10.1056/NEJMoa2107058. Epub 2021 Jun 30.
7
COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence.巴西亚马逊地区的 COVID-19 是由地方性谱系的持续存在和 P.1 出现驱动的。
Nat Med. 2021 Jul;27(7):1230-1238. doi: 10.1038/s41591-021-01378-7. Epub 2021 May 25.
8
Estimating infectiousness throughout SARS-CoV-2 infection course.估算 SARS-CoV-2 感染全程的传染性。
Science. 2021 Jul 9;373(6551). doi: 10.1126/science.abi5273. Epub 2021 May 25.
9
BNT162b2 Messenger RNA Vaccination Did Not Prevent an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 Variant 501Y.V2 in an Elderly Nursing Home but Reduced Transmission and Disease Severity.BNT162b2 信使 RNA 疫苗未能预防老年疗养院严重急性呼吸综合征冠状病毒 2 变异株 501Y.V2 的爆发,但降低了传播和疾病严重程度。
Clin Infect Dis. 2022 Feb 11;74(3):517-520. doi: 10.1093/cid/ciab446.
10
The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients.在新诊断的COVID-19患者的鼻咽样本中,501Y.V2新冠病毒变体的病毒载量介于501Y.V1变体和历史变体之间。
J Infect. 2021 Jul;83(1):119-145. doi: 10.1016/j.jinf.2021.04.023. Epub 2021 Apr 28.